Simon Portsmouth, VP, Head of Clinical Development, Shionogi Shares Insights from the New Data on an Antibiotic to Treat Bacterial Infections

Shots:Simon spoke about the new data on FETROJA (cefiderocol), an antibiotic for the treatment of serious Gram-negative (highly resistant) bacterial infectionsHe also talked about Shionogi’s agreement with GARDP & CHAI for the manufacturing and commercialization of cefiderocol in different countriesThe interview summarizes how Shionogi is advancing by developing medicines to treat serious…